Comparative Pharmacology
Head-to-head clinical analysis: PLACIDYL versus VALMID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLACIDYL versus VALMID.
PLACIDYL vs VALMID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethchlorvynol is a sedative-hypnotic that depresses the central nervous system at the level of the brainstem and reticular formation, potentiating GABAergic inhibition. Its exact molecular mechanism is not fully defined.
Valproate increases gamma-aminobutyric acid (GABA) concentrations in the brain either by inhibiting GABA transaminase or by increasing glutamic acid decarboxylase activity, thereby enhancing inhibitory neurotransmission.
500 mg to 1000 mg orally at bedtime, as a hypnotic. Usual dose is 500 mg to 750 mg. Maximum dose 1000 mg.
250 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 10-40 hours), with prolonged elimination in hepatic impairment and overdose due to saturation of metabolism.
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 10-20 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for 30-40% of metabolites, with enterohepatic recycling.
Renal excretion accounts for >90% of elimination, primarily as unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic